How We Are Changing The Way Cancer Is Treated

Vivos Inc. is a medical device company with its patented Precision Radionuclide Therapy™.  Vivos (OTCQB: RDGL) was incorporated in 2018 to develop an innovative, next-generation, and safer cancer treatment. 

Our proprietary and revolutionary Precision Radionuclide Therapy™ (PRnT™) is dedicated to revolutionizing the way cancer is treated for animals and humans. 

From 2018 to 2024, the focus was on gathering data from our IsoPet® animal cancer division for our RadioGel® human cancer division to support our FDA application for human cancer trials at the Mayo Clinic.  The pet case studies gathered during 2018-2024 started with our first certified veterinary clinic in Kennewick, WA to working with top universities such as the University of Missouri and Johns Hopkins University. In 2024, Vivos Inc. began the commercialization of  IsoPet® across the United States.

Vivos Inc. - The  Leader In Precision Radionuclide Therapy™

Vivos Inc.'s strategic endeavors in medical and veterinary oncology are indeed pushing the boundaries of healthcare innovation. Holding nearly 30 patents including Precision Radionuclide Therapy™ and trademark protection for IsoPet®, RadioGel®, PrecisionGel™, Alpha-Gel™, Beta-Gel™ and Gamma-Gel™ just to name a few, Vivos Inc. is securing its place as the leader in radionuclide therapy.  

Expansion into Veterinary Care with IsoPet®

In 2024, Vivos Inc. began the commercialization of the IsoPet® division and has been expanding its reach in veterinary medicine with a goal of certifying veterinarians in each state in the small animal, equine and exotic animal sector.